Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00035295
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to determine the efficacy and safety of an Treatment of MK0869
in the treatment of depression.
- Detailed Description
The duration of treatment is 8 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 584
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HAMD-17 total score at week 8. Tolerability.
- Secondary Outcome Measures
Name Time Method CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8